



Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress

October 8, 2020

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Oct. 8, 2020-- [Lantheus Holdings, Inc.](#) (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that two abstracts featuring data from the Company's prostate specific membrane antigen artificial intelligence (PSMA AI) tool will be presented at the upcoming European Association of Nuclear Medicine (EANM) Virtual Congress, which will be held from October 22-30, 2020. Details on the presentations are included below.

Oral Presentation

Title: Deep Learning-Enabled Comprehensive Detection and Quantification of 18FDCFPyL (PyL-PSMA) PET/CT

Presenter: Johan Brynolfsson; Data Scientist; EXINI Diagnostics AB, Lund, SWEDEN

Abstract ID: OP-548

Session Title: 1006: Cutting Edge Science Track - TROP Session: AI -Radiomics and Modelling

Date and Time: Saturday, October 24, 2020, 10:40 - 12:10 CEST on an "on demand" basis

e-Poster Presentation

Title: Deep-learning based urinary bladder segmentation using 18FDCFPyL (PyL-PSMA) PET/CT images

Presenter: Johan Brynolfsson; Data Scientist; EXINI Diagnostics AB, Lund, SWEDEN

Abstract ID: EPS-145

Session Title: 1411: e-Poster Presentation Session 9: Physics -Software and Image Processing

Date and Time: Friday, October 30, 2020, 09:00 - 10:30 CEST on an "on demand" basis

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechnoLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Puerto Rico, Canada and Sweden. For more information, visit www.lantheus.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201008005176/en/): <https://www.businesswire.com/news/home/20201008005176/en/>

Investors:

Mark Kinarney
Senior Director, Investor Relations
978-671-8842

Media:

Melissa Downs
Director, Corporate Communications
646-975-2533

Source: Lantheus Holdings, Inc.